nyuuzyou/wikis huggingface dataset:
Retinoblastoma

Back to Top
Last updated on 2024-11-22:1 regimens on this page
2 variants on this page
=Adjuvant therapy=
==CEV (Carboplatin/Etoposide)==
CEV: Carboplatin, Etoposide, Vincristine
===Regimen variant #1, 3 cycles===
Study 	Dates of enrollment	Evidence 	Comparator	Comparative Efficacy
Ye et al. 2024	2013-08 to 2024-03 	Phase 3 (E-de-esc)	CEV x 6 	Non-inferior DFS (primary endpoint)DFS60: 90.4% vs 89.2%
Note: The etoposide instructions are confusing on CT.gov; this will eventually be updated after dosing details in the manuscript have been reviewed.
====Preceding treatment====
*Unilateral enucleation
====Chemotherapy====
*Carboplatin (Paraplatin) by the following age-specific criteria:
**Younger than 3 years old: 18.6 mg/kg IV once on day 1
**3 years old or older: 560 mg/m2 IV once on day 1
*Etoposide (Vepesid) by the following age-specific criteria:
**Younger than 3 years old: 5 mg/kg IV once per day on days 1 & 2
**3 years old or older: 150 mg/m2 IV once per day on days 1 & 2
*Vincristine (Oncovin) by the following age-specific criteria:
**Younger than 3 years old: 0.05 mg/kg IV once on day 1
**3 years old or older: 1.5 mg/m2 IV once on day 1
21-day cycle for 3 cycles
===Regimen variant #2, 6 cycles===
Study 	Dates of enrollment	Evidence 	Comparator	Comparative Efficacy
Ye et al. 2024	2013-08 to 2024-03 	Phase 3 (C)	CEV x 3 	Non-inferior DFS (primary endpoint)DFS60: 89.2% vs 90.4%
Note: The etoposide instructions are confusing on CT.gov; this will eventually be updated after dosing details in the manuscript have been reviewed.
====Preceding treatment====
*Unilateral enucleation
====Chemotherapy====
*Carboplatin (Paraplatin) by the following age-specific criteria:
**Younger than 3 years old: 18.6 mg/kg IV once on day 1
**3 years old or older: 560 mg/m2 IV once on day 1
*Etoposide (Vepesid) by the following age-specific criteria:
**Younger than 3 years old: 5 mg/kg IV once per day on days 1 & 2
**3 years old or older: 150 mg/m2 IV once per day on days 1 & 2
*Vincristine (Oncovin) by the following age-specific criteria:
**Younger than 3 years old: 0.05 mg/kg IV once on day 1
**3 years old or older: 1.5 mg/m2 IV once on day 1
21-day cycle for 6 cycles
===References===
#Ye H, Xue K, Zhang P, Chen R, Zhai X, Ling L, Xiao W, Tang L, Wang H, Mao Y, Ai S, Bi Y, Liu Q, Zou Y, Qian J, Yang H. Three vs 6 Cycles of Chemotherapy for High-Risk Retinoblastoma: A Randomized Clinical Trial. JAMA. 2024 Nov 19;332(19):1634-1641. link to original article link to PMC article dosing details on CT.gov have been reviewed by our editors EuroPMC NCT01906814
Category:Retinoblastoma regimens
Category:Disease-specific pages
Category:Pediatric solid tumors
Revumenib (Revuforj)

==Mechanism of action==
From the NCI Drug Dictionary: An orally bioavailable protein-protein interaction (PPI) inhibitor of the menin-mixed lineage leukemia (MLL; myeloid/lymphoid leukemia; KMT2A) proteins, with potential antineoplastic activity. Upon oral administration, revumenib targets and binds to the nuclear protein menin, thereby preventing the interaction between the two proteins menin and MLL and the formation of the menin-MLL complex. This reduces the expression of downstream target genes and results in an inhibition of the proliferation of MLL-rearranged leukemic cells.
==History of changes in FDA indication==
*2024-11-15: Approved for relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older. (Based on AUGMENT-101)
==Also known as==
*Code name: SNDX-5613
*Brand name: Revuforj
Category:Drugs
Category:Oral medications
Category:Mutation-specific medications
Category:KMT2A inhibitors
Category:Acute leukemia medications
Category:FDA approved in 2024
Rezvilutamide (Ariane)

==Mechanism of action==
From the NCI Drug Dictionary: An orally bioavailable androgen receptor (AR) antagonist with potential antineoplastic activity. Upon administration, rezvilutamide competitively binds to AR in target tissues, which both prevents androgen-induced receptor activation and facilitates the formation of inactive complexes that cannot be translocated to the nucleus. This prevents binding to and transcription of AR-responsive genes, inhibits the expression of genes that regulate prostate cancer cell proliferation, and may lead to an inhibition of cell growth of AR-expressing tumor cells.
==Diseases for which it is used==
*Prostate cancer
==History of changes in NMPA indication==
*2022-06-29: Approved for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) with high tumour burden. (Based on CHART)
==Also known as==
*Code name: SHR-3680
*Brand name: Ariane
Category:Drugs
Category:Oral medications
Category:Second-generation nonsteroidal antiandrogens
Category:Prostate cancer medications
Category:NMPA approved in 2022
Rho(D) immune globulin (RhoGAM)

==General information==
Class/mechanism: Not entirely known. Rho(D) immune globulin forms anti-D-coated red blood cell complexes which are thought to bind to macrophage receptors in the spleen. This is then hypothesized to block the spleen's clearance of antibody-coated cells, which include platelets. Thus, the destruction of platelets in ITP is limited.
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
==Diseases for which it is used==
*Immune thrombocytopenia (ITP)
==Patient drug information==
*Rho(D) immune globulin (RhoGAM) patient drug information (UpToDate)Rho(D) immune globulin (RhoGAM) patient drug information (UpToDate)
==Also known as==
*Brand name: RhoGAM
==References==
Category:Drugs
Category:Intravenous medications
Category:Hematology medications
Category:Immune thrombocytopenia medications
Ribociclib (Kisqali)

==General information==
Class/mechanism: Cyclin-dependent kinase (CDK) 4 and 6 inhibitor. Ribociclib inhibits DNA synthesis and cancer cell growth by blocking activity of the cyclin D-CDK4/6 complex which regulates cell cycle progression and cellular proliferation by phosphorylating the retinoblastoma protein (pRb). Inhibiting pRb phosphorylation has been observed to lead to cell cycle arrest in the G1 phase.Ribociclib (Kisqali) package insert Ribociclib (Kisqali) package insert (locally hosted backup)Kisqali manufacturer's website
Route: PO
Extravasation: n/a
==Diseases for which it is used==
*Breast cancer
==Patient drug information==
*Ribociclib (Kisqali) package insert
==History of changes in FDA indication==
*2017-03-13: Initial FDA approval in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. (Based on MONALEESA-2 and MONALEESA-3)
*2018-07-18: FDA approval expanded in combination with an aromatase inhibitor for pre/perimenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy. (No longer limited to postmenopausal women; based on MONALEESA-7)
*2024-09-17: FDA approved with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. (Based on NATALEE)
==History of changes in EMA indication==
*2017-08-22: Initial authorization
==History of changes in Health Canada indication==
*2018-06-18: Initial notice of compliance in combination with letrozole for treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer as an initial endocrine-based therapy.
*2020-02-07: Expanded indication (details unavailable)
*2023-02-10: Expanded indication (details unavailable)
==Also known as==
*Code names: LEE-011
*Brand names: Kisqali, Kryxana
==References==
Category:Drugs
Category:Oral medications
Category:Protein expression-specific medications
Category:CDK4 inhibitors
Category:CDK6 inhibitors
Category:Breast cancer medications
Category:FDA approved in 2017
Category:EMA approved in 2018
Category:Health Canada approved in 2018
Ricolinostat (ACY-1215)

==General information==
Class/mechanism from the NCI Drug Dictionary: An orally bioavailable, specific inhibitor of histone deacetylase 6 (HDAC6) with potential antineoplastic activity. Ricolinostat selectively targets and binds to HDAC6, thereby disrupting the Hsp90 protein chaperone system through hyperacetylation of Hsp90 and preventing the subsequent aggresomal protein degradation. This leads to an accumulation of unfolded and misfolded ubiquitinated proteins and may eventually induce cancer cell apoptosis, and inhibition of cancer cell growth.Ricolinostat in Multiple Myeloma, Acetylon PharmaceuticalsAndrew J Yee, MD, Peter M. Voorhees, MD, William Bensinger, Jesus G. Berdeja, MD, Jeffrey G Supko, PhD, Paul G. Richardson, David Tamang, PhD, Simon S Jones, PhD, Gretchen Patrick, Catherine Wheeler, MD and Noopur Raje, MD. Ricolinostat (ACY-1215), a Selective HDAC6 Inhibitor, in Combination with Lenalidomide and Dexamethasone: Results of a Phase 1b Trial in Relapsed and Relapsed Refractory Multiple Myeloma. 2014 ASH Annual Meeting abstract 4772. link to abstractNoopur Raje, MD, Parameswaran N Hari, MD, MRCP, MS, Dan T. Vogl, MD, MSCE, Sundar Jagannath, MD, Robert Z. Orlowski, M.D., Ph.D., Jeffrey G Supko, PhD, Patricia Stephenson, ScD, Simon S Jones8, Catherine Wheeler, MD and Sagar Lonial, MD. Rocilinostat (ACY-1215), a Selective HDAC6 Inhibitor, Alone and in Combination with Bortezomib in Multiple Myeloma: Preliminary Results From the First-in-Humans Phase I/II Study. 2012 ASH Annual Meeting abstract 4061. link to abstract
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
==Preliminary data==
===Multiple myeloma===
# Vogl DT, Raje N, Jagannath S, Richardson P, Hari P, Orlowski R, Supko JG, Tamang D, Yang M, Jones SS, Wheeler C, Markelewicz RJ, Lonial S. Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma. Clin Cancer Res. 2017 Jul 1;23(13):3307-3315. Epub 2017 Jan 4. link to original article link to PMC article PubMed
==Also known as==
*Code name: ACY-1215
*Generic name: rocilinostat
==References==
Category:Drugs
Category:Oral medications
Category:HDAC inhibitors
Category:Multiple myeloma medications (investigational)
Category:Investigational drugs
Rilotumumab (AMG-102)

==Mechanism of action==
From the NCI Drug Dictionary: A fully human IgG2 monoclonal antibody directed against the human hepatocyte growth factor (HGF) with potential antineoplastic activity. Rilotumumab binds to and neutralizes HGF, preventing the binding of HGF to its receptor c-Met and so c-Met activation; inhibition of c-Met-mediated signal transduction may result in the induction of apoptosis in cells expressing c-Met.
Route: IV
==Preliminary data==
Note: This is not meant to be an exhaustive list of preliminary results. References included in this section include non-randomized studies published in high-profile journals (e.g., NEJM) and experimental arms of phase 3 RCTs. Inclusion here is not an indication of impending regulatory approval, although many of these drugs do end up receiving approval by a regulatory authority.
===Non-small cell lung cancer===
# Tarhini AA, Rafique I, Floros T, Tran P, Gooding WE, Villaruz LC, Burns TF, Friedland DM, Petro DP, Farooqui M, Gomez-Garcia J, Gaither-Davis A, Dacic S, Argiris A, Socinski MA, Stabile LP, Siegfried JM. Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer. Cancer. 2017 Aug 1;123(15):2936-2944. Epub 2017 May 4 link to original article link to PMC article EuroPMC
==Also known as==
*Code name: AMG-102
Category:Drugs
Category:Intravenous medications
Category:Anti-HGF antibodies
Category:Halted drugs
Rilzabrutinib (PRN-1008)

==General information==
Class/mechanism: BTK inhibitor
Route: PO
Extravasation: n/a
==Preliminary data==
Note: This is not meant to be an exhaustive list of preliminary results. References included in this section include non-randomized studies published in high-profile journals (e.g., NEJM) and experimental arms of phase 3 RCTs. Inclusion here is not an indication of impending regulatory approval, although many of these drugs do end up receiving approval by a regulatory authority.
===Immune thrombocytopenia===
#PRN1008-010: Kuter DJ, Efraim M, Mayer J, Trněný M, McDonald V, Bird R, Regenbogen T, Garg M, Kaplan Z, Tzvetkov N, Choi PY, Jansen AJG, Kostal M, Baker R, Gumulec J, Lee EJ, Cunningham I, Goncalves I, Warner M, Boccia R, Gernsheimer T, Ghanima W, Bandman O, Burns R, Neale A, Thomas D, Arora P, Zheng B, Cooper N. Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia. N Engl J Med. 2022 Apr 14;386(15):1421-1431. link to original article EuroPMC NCT03395210
==Also known as==
*Code name: PRN-1008
Category:Drugs
Category:Oral medications
Category:BTK inhibitors
Category:Immune thrombocytopenia medications (investigational)
Category:Investigational drugs
Ripretinib (Qinlock)

==General information==
Class/mechanism from the NCI Drug Dictionary: An orally bioavailable switch pocket control inhibitor of wild-type and mutated forms of the tumor-associated antigens (TAA) mast/stem cell factor receptor (SCFR) KIT and platelet-derived growth factor receptor alpha (PDGFR-alpha; PDGFRa), with potential antineoplastic activity. Upon oral administration, DCC-2618 targets and binds to both wild-type and mutant forms of KIT and PDGFRa specifically at their switch pocket binding sites, thereby preventing the switch from inactive to active conformations of these kinases and inactivating their wild-type and mutant forms. This abrogates KIT/PDGFRa-mediated tumor cell signaling and prevents proliferation in KIT/PDGFRa-driven cancers. DCC-2618 also inhibits several other kinases, including vascular endothelial growth factor receptor type 2 (VEGFR2; KDR), angiopoietin-1 receptor (TIE2; TEK), PDGFR-beta and macrophage colony-stimulating factor 1 receptor (FMS; CSF1R), thereby further inhibiting tumor cell growth.
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the package insert.
==Diseases for which it is established (work in progress)==
*Gastrointestinal stromal tumor
==History of changes in FDA indication==
*2020-05-15: Approved for adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib. (Based on INVICTUS)
==History of changes in EMA indication==
*2021-11-18: Initial authorization
==Also known as==
*Code name: DCC-2618
*Brand name: Qinlock
Category:Drugs
Category:Oral medications
Category:CSF1R inhibitors
Category:KIT inhibitors
Category:PDGFR inhibitors
Category:TEK inhibitors
Category:VEGFR inhibitors
Category:Gastrointestinal stromal tumor medications 
Category:FDA approved in 2020
Category:EMA approved in 2021
Risedronate (Actonel)

Also known as Actonel Einmal Woechentlich, Actonel O.A.W., Actonel one a week, Actonel Wekelijks, Actonel with Calcium, Atelvia, Benet, Ductonar, Gemfos, Maxidronato, NE 58095, Optinate, Optinate Septimum, Orafix, Osteonate, Osteorise, Ridron, Rised, Risedon, risedronic acid, risedronate sodium, Risendal, Risofos, Sedron, Seralis.
==General information==
Class/mechanism: Bisphosphonate, inhibits osteoclast activity, dissolution of hydroxyapatite crystals, and bone resorption/turnover.Risedronate (Actonel) package insert Risedronate (Actonel) package insert (locally hosted backup)Actonel manufacturer's website
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information. 
==Patient drug information==
*Patient counseling information can be found on page 33-39 of the Risedronate (Actonel) package insert
*Risedronate (Actonel) patient drug information (UpToDate)Risedronate (Actonel) patient drug information (UpToDate)
==Also known as==
*Brand names: Actonel, Orafix, Ribone, Risedol, Risofos
==References==
Category:Drugs
Category:Oral medications
Category:Bisphosphonates
Category:FDA approved in 1998
Rituximab-rixa (Rixathon)

Note: this is a rituximab biosimilar. It was not granted FDA approval but is approved in Europe.
==Also known as==
*Code name: GP-2013
*Brand name: Rixathon
Category:Drugs
Category:Intravenous medications
Category:Neutral
Category:Anti-CD20 antibodies
Category:Biosimilars
Category:EMA approved in 2017
Category:Stub
Rituximab and hyaluronidase human (Rituxan Hycela)

==General information==
Class/mechanism: Anti-CD20 antibody, chimeric murine/human monoclonal IgG1 kappa, which binds to CD20 (human B-lymphocyte-restricted differentiation antigen, Bp35), which is expressed on B-cells. The Fc domain recruits immune effector functions to mediate B-cell lysis. Possible mechanisms of cell lysis include complement-dependent cytotoxicity (CDC) and antibody-dependent cell mediated cytotoxicity (ADCC).
Route: SC* (Rituxan Hycela treatment should be initiated only after patients have received at least one full dose of a rituximab product by intravenous infusion)
*Rituximab (Rituxan) desensitization protocol
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
==Diseases for which it is established (work in progress)==
*Chronic lymphocytic leukemia
*Diffuse large B-cell lymphoma
*Follicular lymphoma
==Diseases for which it is used==
*Waldenström macroglobulinemia
==Patient drug information==
To be completed
==History of changes in FDA indication==
*2017-06-22: Approved for relapsed or refractory follicular lymphoma (FL) as a single agent. (No supporting studies are cited)
*2017-06-22: Approved for previously untreated FL in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in combination with chemotherapy, as single-agent maintenance therapy. (Based on SABRINA)
*2017-06-22: Approved for non-progressing (including stable disease), FL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. (No supporting studies are cited)
*2017-06-22: Approved for previously untreated diffuse large B-cell lymphoma (DLBCL) in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens. (Based on MabEase)
*2017-06-22: Approved for previously untreated and previously treated CLL in combination with fludarabine and cyclophosphamide (FC). (Based on SAWYER)
==Also known as==
*Brand name: Rituxan Hycela
==References==
Category:Drugs
Category:Subcutaneous medications
Category:Anti-CD20 antibodies
Category:Chronic lymphocytic leukemia medications
Category:Diffuse large B-cell lymphoma medications
Category:Follicular lymphoma medications
Category:Waldenström macroglobulinemia medications
Category:FDA approved in 2017
Rivaroxaban (Xarelto)

==General information==
Class/mechanism: Factor Xa inhibitor, acts at the active site of factor Xa to inhibit its actions in the coagulation cascade.Rivaroxaban (Xarelto) package insert Rivaroxaban (Xarelto) package insert (locally hosted backup)Xarelto manufacturer's website
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
==Reversal information==
Andexanet alfa (Andexxa) can bind, sequester, and reverse the anticoagulation effect of rivaroxaban and apixaban.
==Diseases for which it is used==
*Atrial fibrillation
*Venous thromboembolism
==Patient drug information==
*Rivaroxaban (Xarelto) package insert
*Rivaroxaban (Xarelto) patient drug information (UpToDate)Rivaroxaban (Xarelto) patient drug information (UpToDate)
==History of changes in FDA indication==
*2011-07-01: Approved for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery.
*2011-11-04: Approved to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. (Non-hematologic indication)
*2012-11-02: Approved for the treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and for the reduction in the risk of recurrence of DVT and of PE.
==History of changes in EMA indication==
*2008-09-30: Initial authorization
==History of changes in PMDA indication==
*2015-09-24: New additional indication and a new dosage for the treatment and prevention of recurrence of deep vein thrombosis and pulmonary thromboembolism.
*2021-01-22: New indication and a new additional pediatric dosage for the treatment and prevention of recurrent venous thromboembolism.
==Also known as==
*Code name: BAY-59-7939
*Brand name: Xarelto
==References==
Category:Drugs
Category:Oral medications
Category:Direct oral anticoagulants
Category:Factor Xa inhibitors
Category:Heparin-induced thrombocytopenia medications
Category:Venous thromboembolism medications
Category:EMA approved in 2008
Category:FDA approved in 2011